The role of inflammation in patients with intraductal mucinous neoplasm of the pancreas and in those with pancreatic adenocarcinoma

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3801-3805

  Pezzilli, Raffaele ^a   Corsi, Massimiliano M ^b   Barassi, Alessandra ^b   Morselli Labate, Antonio M ^a   Dogliotti, Giada ^b   Casadei, Riccardo ^a   Corinaldesi, Roberto ^a   D'Eril, Gianvico Melzi ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Matrix metalloproteinase 2; Pancreatic neoplasms; Placental growth factor; Transforming growth factor alpha; Transforming growth factor beta 1; Tumour necrosis factor receptor 1

Indexed keywords

GELATINASE A; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1; AUTACOID;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; BLOOD; COLLOID CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; AGED; CARCINOMA, PANCREATIC DUCTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; PANCREATIC NEOPLASMS;

EID: 77958535844     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Fritz S, Warshaw AL and Thayer SP: Management of mucin-producing cystic neoplasms of the pancreas. Oncologist 14: 125-36, 2009.
2. Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine NR, Scarpa A and Accolla RS: Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 48: 301-311, 1996.
3. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G and Rodeck U: Tumor-associated transforming growth factor-beta and interleukin- 10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155: 537-547, 1999.
4. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and Kalthoff H: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58: 1741-1749, 1998.
5. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS and Eberlein TJ: Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125: 73-84, 1999.
6. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B and Kalthoff H: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(Suppl): 925s-932s, 2001.
7. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M and Emanuelli G: Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 55: 684-698, 2006.
8. Schomber T, Kopfstein L, Djonov V, Albrecht I, Baeriswyl V, Strittmatter K and Christofori G: Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 67: 10840-10848, 2007.
9. Booth BW, Jhappan C, Merlino G and Smith GH: TGFbetal and TGFalpha contrarily affect alveolar survival and tumorigenesis in mouse mammary epithelium. Int J Cancer 120: 493-499, 2007. (Pubitemid 44969018)
10. Grewal IS: Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv Exp Med Biol 647: 1-7, 2009.
11. Bramhall SR, Neoptolemos JP, Stamp GW and Lemoine NR: Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 182: 347-55, 1997.
12. WHO: Obesity: preventing and managing the global epidemic. WHO Technical Report Series 894 Geneva 2000.
13. Pezzilli R, Barassi A, Morselli-Labate AM, Fantini L, Tomassetti P, Campana D, Casadei R, Finazzi S, d'Eril GM and Corinaldesi R: Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. J Gastroenterol 42: 754-760, 2007.
14. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, Tsao PN, Jan IS and Wong JM: Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 37: 145-150, 2008.
15. Roy H, Bhardwaj S and Ylä-Herttuala S: Biology of vascular endothelial growth factors. FEBS Lett 580: 2879-2887, 2006.
16. Casneuf VF, Demetter P, Boterberg T, Delrue L, Peelers M and Van Damme N: Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol Rep 22: 105-113, 2009.
17. Smith J, Derynck R and Korc M: Production of transforming growth factor a in human pancreatic cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 84: 7567-7570, 1987.
18. Tahara E: Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 116: 121-131, 1990. (Pubitemid 20271913)
19. Moskal TL, Huang S, Ellis LM, Fritsche HA Jr. and Chakrabarty S: Serum levels of transforming growth factor alpha in gastrointestinal cancer patients. Cancer Epidemiol Biomarkers Prev 4: 127-131, 1995.
20. Ellingsworth I, Derynck R and Voorhees I: Overexpression of transforming growth factor a in psoriatic epidermis. Science 243: 811-814, 1989.
21. Schultz G, Rotatori D and Clark W: EGF and TGF-α in wound healing and repair. J Cell Biochem 45: 350-352, 1991.
22. Piek E and Roberts AB: Suppressor and oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis. Adv Cancer Res 83: 1-54, 2001.
23. Kleeff J, Friess H, Simon P, Susmallian S, Büchler P, Zimmermann A, Büchler MW and Korc M: Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Dig Dis Sci 44: 1793-1802, 1999. (Pubitemid 29446842)
24. Lin Y, Kikuchi S, Tamakoshi A, Obata Y, Yagyu K, Inaba Y, Kurosawa M, Kawamura T, Motohashi Y, Ishibashi T and JACC Study Group: Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan). Cancer Causes Control 17: 1077-1082, 2006.
25. Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 9: 541-573, 1993. (Pubitemid 23346108)
26. Musso O, Theret N, Campion JP, Turlin B, Milani S, Grappone C and Clement B: In situ detection of MMP-2 and TIMP-2 transcripts in human primary hepatocellular carcinoma and liver metastasis. J Hepatol 26: 593-605, 1997.
27. Emonard HP, Remacle AG, Noel AC, Grimaud JA, Stetler-Stevenson WG and Foidart JM: Tumor cell surface-associated binding site for the Mr 72,000 type IV collagenase. Cancer Res 52: 5845-5848, 1992.
28. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL and Lenardo MJ: A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354, 2000.
29. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17: 331-367, 1999.
30. MacEwan DJ: TNF ligands and receptors: a matter of life and death. Br J Pharmacol 135: 855-875, 2002. (Pubitemid 34214444)
31. Yousaf N, Gould DJ, Aganna E, Hammond L, Mirakian RM, Turner MD, Hitman GA, McDermott MF and Chemajovsky Y: Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation. Arthritis Rheum 52: 2906-2916, 2005.